Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (331-340 of 578) with videos related to

Pageof 58
Sort By:
Nature Biotechnology|December 20, 2011
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencingJoke Reumers, Peter De Rijk, Hui Zhao, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 5, 2020
European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancerDavid Cibula, François Planchamp, Daniela Fischerova, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of the National Cancer Institute|August 16, 2011
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancerChee K Lee, Michael Friedlander, Chris Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 13, 2011
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational studyBen Van Calster, Lil Valentin, Caroline Van Holsbeke, et al.
BMJ (Clinical Research Ed.)|December 16, 2010
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupDirk Timmerman, Lieveke Ameye, Daniela Fischerova, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2020
Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)Irena Rohr, Sara Alavi, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinomaEleftherios P Diamandis, Andreas Scorilas, Stefano Fracchioli, et al.
Pageof 58

Showing results (331-340 of 578) with videos related to

Sort By:
Pageof 58
Nature Biotechnology|December 20, 2011
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencingJoke Reumers, Peter De Rijk, Hui Zhao, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 5, 2020
European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancerDavid Cibula, François Planchamp, Daniela Fischerova, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
British Journal of Cancer|November 9, 2016
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancerJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Journal of the National Cancer Institute|August 16, 2011
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancerChee K Lee, Michael Friedlander, Chris Brown, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 13, 2011
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational studyBen Van Calster, Lil Valentin, Caroline Van Holsbeke, et al.
BMJ (Clinical Research Ed.)|December 16, 2010
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA groupDirk Timmerman, Lieveke Ameye, Daniela Fischerova, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 7, 2020
Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)Irena Rohr, Sara Alavi, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinomaEleftherios P Diamandis, Andreas Scorilas, Stefano Fracchioli, et al.
Pageof 58